Shanghai, August 31, 2016 – Betta Pharmaceuticals Co., Ltd. has successfully received X-396 CFDA IND approval in the class 1.1 IND application. The innovative target therapy, X-396, is aim to provide treatments for ALK positive and NSCLC patients that developed progression with crizotinib treatment. Sundia is honored to have contributed to and assisted in conducting pre-clinical CMC ( synthesis, formulation, and analysis) study as well as facilitating the successful on-site verification by the PFDA.

Register Now!
Webinar: New Modality - Peptides Innovations and a Comprehensive Synthetic Peptide Drug Discovery Platform
June 19, 2024 at 10am ET / 07am PT / 04pm CET
View more
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all